Gordon Stuart C, Lamerato Lois E, Rupp Loralee B, Holmberg Scott D, Moorman Anne C, Spradling Philip R, Teshale Eyasu, Xu Fujie, Boscarino Joseph A, Vijayadeva Vinutha, Schmidt Mark A, Oja-Tebbe Nancy, Lu Mei
Division of Gastroenterology and Hepatology, Henry Ford Health System, Detroit, Michigan, USA.
Department of Public Health Sciences, Henry Ford Health System, Detroit, Michigan, USA.
Am J Gastroenterol. 2015 Aug;110(8):1169-77; quiz 1178. doi: 10.1038/ajg.2015.203. Epub 2015 Jul 28.
The severity of liver disease in the hepatitis C virus (HCV)-infected population in the United States remains uncertain. We estimated the prevalence of cirrhosis in adults with chronic hepatitis C (CHC) using multiple parameters including liver biopsy, diagnosis/procedure codes, and a biomarker.
Patients enrolled in the Chronic Hepatitis Cohort Study (CHeCS) who received health services during 2006-2010 were included. Cirrhosis was identified through liver biopsy reports, diagnosis/procedure codes for cirrhosis or hepatic decompensation, and Fibrosis-4 (FIB-4) scores ≥5.88. Demographic and clinical characteristics associated with cirrhosis were identified through multivariable logistic modeling.
Among 9,783 patients, 2,788 (28.5%) were cirrhotic by at least one method. Biopsy identified cirrhosis in only 661 (7%) patients, whereas FIB-4 scores and diagnosis/procedure codes for cirrhosis and hepatic decompensation identified cirrhosis in 2,194 (22%), 557 (6%), and 482 (5%) patients, respectively. Among 661 patients with biopsy-confirmed cirrhosis, only 356 (54%) had an International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code for cirrhosis. Older age, male gender, Asian race, Hispanic ethnicity, genotype 3 infection, HIV coinfection, diabetes, history of antiviral therapy, and history of alcohol abuse were independently associated with higher odds of cirrhosis (all, P<0.05). Conversely, private health insurance coverage, black race, and HCV genotype 2 were associated with lower odds of cirrhosis.
A high proportion of patients with biopsy-confirmed cirrhosis are not assigned ICD-9 codes for cirrhosis. Consequently, ICD-9 codes may not be reliable as the sole indicator of the prevalence of cirrhosis in cohort studies. Use of additional parameters suggests a fourfold higher prevalence of cirrhosis than is revealed by biopsy alone. These findings suggest that cirrhosis in CHC patients may be significantly underdocumented and underdiagnosed.
美国丙型肝炎病毒(HCV)感染人群中肝病的严重程度仍不确定。我们使用包括肝活检、诊断/程序编码和一种生物标志物在内的多个参数估计了慢性丙型肝炎(CHC)成人患者中肝硬化的患病率。
纳入2006年至2010年期间接受医疗服务的慢性丙型肝炎队列研究(CHeCS)患者。通过肝活检报告、肝硬化或肝失代偿的诊断/程序编码以及纤维化-4(FIB-4)评分≥5.88来确定肝硬化。通过多变量逻辑模型确定与肝硬化相关的人口统计学和临床特征。
在9783例患者中,至少有一种方法诊断为肝硬化的有2788例(28.5%)。肝活检仅在661例(7%)患者中确诊肝硬化,而FIB-4评分以及肝硬化和肝失代偿的诊断/程序编码分别在2194例(22%)、557例(6%)和482例(5%)患者中确诊肝硬化。在661例经活检确诊为肝硬化的患者中,只有356例(54%)有国际疾病分类第九版临床修订本(ICD-9-CM)肝硬化编码。年龄较大、男性、亚洲种族、西班牙裔、3型基因型感染、合并HIV感染、糖尿病、抗病毒治疗史和酗酒史与肝硬化几率较高独立相关(均P<0.05)。相反,私人医疗保险覆盖、黑人种族和HCV 2型基因型与肝硬化几率较低相关。
经活检确诊为肝硬化的患者中,很大一部分未被赋予ICD-9肝硬化编码。因此,在队列研究中,ICD-9编码作为肝硬化患病率的唯一指标可能不可靠。使用其他参数显示肝硬化患病率比仅通过活检揭示的高四倍。这些发现表明,CHC患者中的肝硬化可能记录严重不足且诊断不足。